This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	IL-2	<p>Mouse studies suggest a complex composed of an IL-2 mAb and IL-2 could help improve the ability of cancer vaccines to prevent relapse in patients with lymphoma. In mice with minimal residual lymphoma, a cancer vaccine combined with i.p. infusion of the IL-2 mAb-IL-2 complex resulted in 60% of the animals surviving for more than 100 days versus 20% for vaccine alone and 0% for no treatment. Next steps include developing other cytokine-based compounds and testing them with the vaccine in humanized mouse models of cancer.</p> <p>Heat Biologics Inc. uses its Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology platform to create vaccines adjuvanted with allogeneic cancer cells that continually secrete heat shock 90 kDa protein β1 (Hsp90B1; GP96; GRP94). The company's most advanced ImPACT cancer vaccine is HS-110, which is in Phase II testing for non-small cell lung cancer (NSCLC).</p> <p>SciBX 7(17); doi:10.1038/scibx.2014.490 Published online May 1, 2014</p>	Cancer vaccine patented; licensed to Heat Biologics	<p>Newman, R.G. <i>et al. Blood</i>; published online March 31, 2014; doi:10.1182/blood-2013-08-520775 Contact: Robert B. Levy, University of Miami Miller School of Medicine, Miami, Fla. e-mail: rlevy@med.miami.edu</p>